“What was striking was not simply that mitochondrial transfer was being discussed, but how many different cancer systems it appeared to connect. Across all three talks, mitochondria were presented less as isolated organelles and more as mobile biological assets shaping metastasis, immune exhaustion, therapeutic resistance, and even tumor innervation. You could feel the field beginning to connect previously separate observations into a larger systems-level framework.”
— Alex Sercel, Co-Founder, MitoWorld.org
For decades, mitochondria occupied an uneasy place in cancer research. Everyone knew they mattered. They appeared in discussions of metabolism, apoptosis, oxidative stress, and cellular energetics. But they rarely occupied center stage at major oncology meetings. The mitochondrion was often treated as background infrastructure — essential, certainly, but secondary to the “real” drivers of cancer biology.
Something changed at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego.
For the first time in the history of the AACR Annual Meeting, mitochondrial transfer in cancer was given its own dedicated symposium. That may sound procedural to outsiders, but to researchers working at the intersection of mitochondria, metabolism, immunology, and cancer, it represented something much larger: institutional recognition that mitochondrial dynamics are no longer peripheral to oncology. They are becoming central to it.
The symposium, “Mitochondrial Transfer Networks in Cancer Progression,” brought together three researchers approaching the field from distinct but converging directions:
- Yosuke Togashi, Okayama University
- Simon Grelet, University of South Alabama / Mitchell Cancer Institute
- Luca Gattinoni, University of Regensburg / Leibniz Institute for Immunotherapy (LIT)
Collectively, the presentations argued something profound: mitochondrial transfer is not a niche biological curiosity. It is emerging as a fundamental mode of intercellular communication in cancer biology — one that tumors exploit, immune systems respond to, and future therapies may intentionally manipulate.
After the session, MitoWorld.org reached out to all three panelists with a series of questions about the field, the symposium, and where mitochondrial cancer biology may be headed next. What emerged from those conversations was not just enthusiasm, but the unmistakable sense that an entire area of science is crystallizing in real time.
A Field Arrives
When asked what made the AACR symposium so important, all three researchers independently focused on the same point: this was a first.
“This was, to my knowledge, the first time mitochondrial transfer in cancer had been given its own dedicated special session at AACR,” explained Simon Grelet. “The room was charged with enthusiasm and curiosity.”
Yosuke Togashi emphasized the scale of interest from the oncology community itself:
“The sheer volume of questions indicated a significant surge in interest regarding how mitochondrial dynamics influence oncology.”
For Luca Gattinoni, the significance was not merely that the session existed, but how it was framed.
“The three talks together made an argument that no single one of us could have made alone: that mitochondrial transfer is not a niche phenomenon but a fundamental mode of intercellular communication that tumors exploit and that we can potentially exploit back.”
That framing matters.
Cancer biology has increasingly become the biology of systems: tumor microenvironments, immune interactions, stromal signaling, metabolism, and cellular networking. What mitochondrial transfer research suggests is that mitochondria themselves may function as active biological currency moving between cells — influencing survival, adaptation, immune suppression, metastasis, and therapeutic resistance.
From “Power Plants” to Networks
One of the strongest themes emerging from the symposium was that the classical textbook view of mitochondria is rapidly collapsing.
For generations, mitochondria were taught primarily as intracellular energy factories — isolated organelles generating ATP inside sealed cellular boundaries.
That view now appears incomplete.
“The field is moving away from the traditional view of the mitochondrion as an isolated ‘power plant’ enclosed within a cell,” said Yosuke Togashi. “Instead, we are beginning to understand it as a dynamic component of a larger networking system.”
That conceptual shift may ultimately prove as important as any individual experiment.
Mitochondria are increasingly being understood not simply as metabolic engines, but as signaling entities, stress sensors, inflammatory regulators, and now potentially mobile intercellular participants capable of moving between cells and altering biological outcomes.
Simon Grelet noted how rapidly evidence for mitochondrial transfer has accumulated across multiple dimensions of cancer biology:
“It is proving to touch multiple dimensions of cancer biology: how tumor cells acquire metabolic advantages, how they interact with their microenvironment, how they evade treatment, and more.”
Meanwhile, Luca Gattinoni highlighted how evidence is arriving simultaneously from very different domains:
“Nerve-tumor interactions shaping metastasis, tumor cells offloading dysfunctional mitochondria to suppress immune responses, stromal cells using the same mechanism to sustain T cell fitness.”
“The same biological currency,” he added, “deployed in radically different contexts.”
The Room Itself Told the Story
Scientific meetings often reveal the future of a field less through formal presentations than through hallway conversations afterward.
By all accounts, that happened here.
Yosuke Togashi was struck not only by the engagement during the session, but by what happened after it ended:
“The technical nature of the follow-up questions showed that researchers are already thinking about how to integrate these concepts into their own models.”
Luca Gattinoni described something rarer still:
“The conversation that emerged felt like the field thinking out loud in real time.”
That may ultimately be the most important signal of all.
Not simply that mitochondrial transfer research is growing, but that cancer researchers working in metastasis, immunotherapy, stromal biology, metabolism, and genomics are beginning to realize they are asking overlapping questions about the same underlying system.
The Next Frontier: mtDNA and the Mitonuclear System
If mitochondrial transfer itself is emerging as a major area, the next wave may center on mtDNA and the mitonuclear system.
The mitochondrial genome remains one of the least fully integrated components of modern cancer biology. Heteroplasmy, mutation dynamics, mitochondrial-nuclear coordination, and intercellular mitochondrial inheritance remain only partially understood.
Yosuke Togashi believes advancing sequencing technologies will rapidly change that.
“While the complexities of mutation patterns and heteroplasmy remain largely mysterious, advancing sequencing technologies will soon make this a focal point of cancer genomics.”
Luca Gattinoni sees the mitonuclear axis becoming its own frontier:
“We now have enough mechanistic footing to ask harder questions about directionality, selectivity, and what it truly means for a cell to absorb another cell’s mitochondria and their DNA.”
And perhaps most intriguingly, he believes the future will move beyond observation:
“The ambition should grow: not just observing transfer, but engineering it with intent.”
That single sentence hints at where this field could eventually lead: mitochondrial engineering, mitochondrial immunotherapy, and perhaps entirely new therapeutic architectures built around manipulating cellular energy and signaling systems directly.
A New Scientific Convergence
Historically, mitochondrial biologists and cancer researchers often existed in adjacent but separate scientific cultures. That separation may now be ending.
Simon Grelet noted that mitochondrial biology appeared across multiple AACR tracks far beyond this single symposium.
Meanwhile, Yosuke Togashi offered perhaps the most insightful observation of the entire discussion:
“The most vital ‘transfer’ occurring right now isn’t just between cells, but between disciplines.”
That may ultimately define this moment.
Cancer biology, immunology, mitochondrial medicine, metabolism, genomics, and systems biology are beginning to converge around a shared realization: mitochondria are not passive background organelles. They are dynamic participants in disease.
AACR 2026 may be remembered as one of the first moments when that convergence became visible at scale.
And if the energy in San Diego was any indication, this is only the beginning.
At the Fusion “Mitochondria & Cell Fate Transitions: From Stemness to Senescence” in
St. Julian’s, Malta, May 10–13, the organizers are bringing together are bringing together mitochondrial and STEM cell biologists to better understand cell-fate mechanisms.
The conference organizers, Drs. Mireille Khacho (University of Ottawa), Elisa Motori (University of Cologne), and Maria Eugenia Soriano (University of Padova), will bring together a range of researchers from different disciplines to connect mitochondrial dynamics, metabolism, redox signaling, and organelle communication with cell-fate decisions.
“Lots of exciting mitochondrial research is being done, but it tends to exist in silos,” said Dr. Khacho. “We want to break down those silos to get beyond simple correlations and on to a mechanistic understanding. As the title says, we want to cover mitochondria from stemness to senescence.”
The Conference will bring together leaders across mitochondrial biology, stem cell biology, aging, metabolism, and disease to explore how mitochondrial state actively governs cell fate transitions. Rather than treating mitochondria as passive bioenergetic organelles, the meeting centers on their roles as dynamic regulators of signaling, gene expression, immune crosstalk, and cellular identity across contexts ranging from development and regeneration to degeneration and senescence.
The Conference organizers have multiple goals. They hope to establish new conceptual frameworks for mitochondria-driven cell fate control, enable cross-disciplinary collaborations, and identify new therapeutic possibilities.
Arising frontiers and challenges will be featured. These include understanding the causality between mitochondrial remodeling and fate transitions, how mitochondrial diversity shapes distinct signaling trajectories and functional outcomes, how mitochondrial dynamics connects with transcriptional and epigenetic regulation, how mitochondria-driven senescence programs are distinct from classical damage-induced models, and how single-cell and spatial approaches can be integrated to capture mitochondrial function in vivo.
This meeting is specifically designed for investigators and trainees working in mitochondrial biology and dynamics, stem cell biology and regeneration, aging, senescence, and cell stress responses, cancer cell plasticity and immune–metabolic crosstalk, systems biology, metabolomics, and advanced imaging.
“The conference will be highly interactive plenty of early-career investigators and time for discussion,” said Dr. Khacho. “We hope to see you in Malta.”
For more information and to review the program and confirmed speakers, please visit the Fusion Conference webpage: https://fusion-conferences.com/conference/197.
Questions for the organizers:
MitoWorld: The Conference title (i.e., From Stemness to Senescence) covers a lot of ground. How did you pick the topics and speakers to bring this all together?
Organizers: The title was chosen to reflect both a biological continuum and a physiological trajectory, from normal stemness and regenerative capacity to pathological states, such as dysfunction, degeneration, and senescence. We deliberately selected topics and speakers that sit at key transition points, where cells change identity, competence, or trajectory, because these are moments when mitochondria their roles extending far beyond energy provision to encompass signaling, adaptation, and cell fate determination. Speakers were chosen for both scientific excellence and conceptual complementarity, bringing together perspectives from stem cell biology, aging, cancer, immunity, and neurobiology to create dialogue across traditionally separate fields.
MitoWorld: You have some outstanding goals for the Conference (e.g., “establish new conceptual frameworks for mitochondria-driven cell fate control”). What was the process to arrive at these, and will anyone attempt to synthesize any conclusions from the discussions?
Organizers: The goals emerged from ongoing discussions among the us three co-organizers, where a recurring challenge was the lack of shared frameworks linking mitochondrial changes to cell fate decisions. When FUSION announced the opportunity to propose a new conference topic, it felt like the right moment—a signal, almost—to turn our ongoing informal discussions into a collective effort. Rather than imposing predefined models, we designed the conference to allow concepts to evolve through discussion. We are planning moderated discussion sessions and thematic synthesis moments, and we intend to explore a post-conference summary or perspective to capture key insights, open questions, and future directions.
MitoWorld: Stem cells are a powerful tool, but also a subject in their own right. I understand you have a special connection to STEM cells and mitochondria. How do you hope the conference will be able to differentiate and yet combine these two goals?
Organizers: Stem cells offer a unique lens through which to study plasticity, commitment, and loss of regenerative potential, processes in which mitochondria play an instructive role. The conference does not treat stem cells as a niche topic, nor mitochondria as background machinery. Instead, stem cells are used as a conceptual framework to ask broader questions about how mitochondrial state encodes fate decisions, questions that extend naturally to aging tissues, cancer, and immune cells.
MitoWorld: Mitochondria research has had some controversies, one of which is the split between specific research findings or facts and adding more directly to basic scientific understanding. Do you anticipate that this Conference will provide an opportunity to re-set that balance?
Organizers: Yes. Many translational efforts in mitochondrial biology have been limited by incomplete mechanistic understanding, and we see real value in tightening that connection. This conference emphasizes mechanism-driven biology while remaining grounded in physiological and disease-relevant contexts. By bringing together basic scientists and translational researchers in a highly interactive format, we aim to foster a more integrated approach in which rigorous discovery and meaningful application inform one another.
MitoWorld: What specific provisions have you made to ensure that trainees will have quality time with the more experienced researchers? And in the future is there a way to make these events more accessible and affordable for them?
Organizers: We’ve been fortunate to build on the FUSION format, which inherently supports trainee engagement through its small size, shared meals, and extended discussion periods. This naturally creates space where early career researchers can interact meaningfully with more senior scientists. We further prioritized trainees through short talks selected from abstracts, dedicated poster sessions, “meet the poster presenters” session and informal networking opportunities. We have also worked diligently to secure funds, in the form of travel awards, for trainees and early career researchers.
MitoWorld: This Conference promises to be an outstanding event. What plans do you have to sustain the momentum?
Organizers: We’re pleased that the ambition and enthusiasm we’ve invested in this conference concept are immediately recognizable. We view this conference as the foundation of an ongoing scientific effort rather than a one-time event. Our intention is to establish Mitochondria & Cell Fate Transitions as a recurring meeting held every other year, creating continuity and an evolving forum for the field. Between meetings, we aim to sustain momentum through continued engagement via platforms such as MitoWorld. This structure allows ideas, debates, and emerging frameworks to mature over time while keeping the community connected and forward-looking.
Conference Organizers:
Mireille Khacho (University of Ottawa) investigates how physiological changes in mitochondrial dynamics and metabolism regulate stem cell fate, function, and regeneration. Her work focuses on mitochondrial-dependent metabolite and redox signaling in physiological contexts, and how disruption of these pathways drives neuromuscular diseases, aging and mitochondria-driven senescence.
Elisa Motori (University of Cologne) investigates how cell type–specific mitochondrial and metabolic programs shape brain health and disease vulnerability, revealing energy-driven mechanisms that govern development, resilience, and neurodegeneration.
Maria Eugenia Soriano (University of Padova) investigates how mitochondrial structure and dynamics are transcriptionally regulated to shape cellular metabolism. Using physiological and disease-relevant models, her work integrates mitochondrial biology, metabolic regulation, and gene expression to uncover how alterations in mitochondrial organization drive metabolic rewiring in cancer and other pathologies.
Get ready for the Cell, Multifaceted Mitochondria Symposium, this year in Glasgow, Scottland, June 21–23.
Like its five biennial predecessors, the Glasgow gathering features the hallmark of the Multifaceted Mitochondria Symposia—a broad and deep array of mitochondrial topics and talks, covering a number of areas of inquiring, including mitochondrial biochemistry and bioenergetics, mitochondria homeostasis and stress response, mitochondrial dynamics and transfer, mitochondrial communication, mitochondria in metabolism, and mitochondria in inflammation and disease. The 2026 event is organized by Isha Jain, Arc Institute and Gladstone/UCF and Thomas Langer, Max Planck Institute for the Biology of Ageing.
Keynotes
Keynote include Judy Hirst, University of Cambridge, and Jared Rutter, University of Utah.
Hirst is a British chemist and mitochondrial biologist at the University of Cambridge, where she is Director of the MRC Mitochondrial Biology Unit and Professor of Biological Chemistry. She leads research into the structure and mechanisms of mitochondrial respiratory enzymes, particularly respiratory complex I, using biochemical and structural methods to understand energy conversion. Hirst is a Fellow of the Royal Society and Fellow of the Academy of Medical Sciences, recognized for her contributions to mitochondrial biology.
Rutter is Distinguished Professor of Biochemistry and holds the Dee Glen and Ida Smith Endowed Chair for Cancer Research at the University of Utah where he has been on the faculty in the Department of Biochemistry since 2003. In 2015, Dr. Rutter was appointed as an Investigator of the Howard Hughes Medical Institute. The Rutter laboratory has identified the functions of several previously uncharacterized mitochondrial proteins, including the discovery of the long-sought mitochondrial pyruvate carrier.
History
The Cell Symposia series on Multifaceted Mitochondria, inaugurated in 2015 in Chicago, has charted the dynamic evolution of mitochondrial research over the past decade. The inaugural meeting focused on foundational themes, such as mitochondrial metabolism and bioenergetics, signaling pathways, mitochondrial dynamics, mitophagy, and quality control. The meeting brought together leaders exploring both basic mitochondrial functions and their intersections with disease, setting a strong mechanistic foundation for the field.
Since then, the symposium has progressively broadened its scope to capture the expanding complexity of mitochondrial biology. By 2022, Jodi Nunnari was the keynote, and the program integrated emerging topics, including mitochondrial communication with other organelles and immune signaling, mitochondrial proteostasis, and the role of mitochondria in inflammation and cancer metabolism. In 2024, several of the www.MitoWorld.org Scientific Advisory Board featured a MitoWorld Initiative. The latest 2026 program anticipates an even wider lens, framing mitochondria as central metabolic and signaling hubs influencing organismal homeostasis, aging, and multi-system diseases. This evolution reflects not only scientific advances but also a growing recognition of mitochondria as versatile regulators and therapeutic targets, a narrative underscored by recurring contributions from influential researchers.
Symposium organizers
Salvatore Fabbiano, Editor-in-Chief, Cell Metabolism, received his PhD in Physiology at the University of Salamanca, where he studied signaling pathways involved in cardiometabolic diseases. He then moved to the University of Geneva to work on host-microbiota homeostasis. He joined Cell Press in 2018.
Shawnna Buttery, Editor-in-Chief, Cell Reports, whose training in the laboratory was in cell biology, studying the cytoskeleton in nematodes as a graduate student at Florida State University and as a postdoc at Dana-Faber Cancer Institute. She has been with Elsevier/Cell Press since 2012.
Thomas Langer, academic co-organizer, who since 2018, has been Director at the Max Planck Institute for the Biology of Ageing in Cologne, focusing on the analysis of mitochondrial proteostasis and its regulation in ageing and age-associated diseases. Langer earned his PhD from the LMU Munich working on chaperone-mediated protein folding and was a researcher at the Memorial Sloan Kettering Cancer Center in New York and professor at the University of Cologne, where he studied the role of mitochondrial protein quality control in neurodegeneration.
Isha Jain, academic co-organizer, associate investigator at the Gladstone Institutes, as well as an assistant professor at UC San Francisco. Jain received her undergraduate degree in chemical and physical biology from Harvard University. There, she worked in the lab of Erin O’Shea on bacterial chromosome segregation. Subsequently, she joined the Harvard-MIT Program in health sciences and technology. She earned a PhD in computer science and systems biology and worked in the labs of Vamsi Mootha and Warren Zapol, where she made the discovery that hypoxia could serve as a therapy for mitochondrial disorders.
MitoWorld Interview
MitoWorld: What makes our Multifaceted Mitochondria meeting unique?
Fabbiano: The mitochondria field is extremely diverse, with researchers working on this organelle from signaling, structural, and bioenergetic perspectives and investigating how they affect cellular, tissue and whole-body homeostasis. This variety of angles is then put in the context of communicable and non-communicable diseases, spanning from the response to infections to metabolic and autoimmune disorders, cancer and aging.
Buttery: Multifaceted Mitochondria stands out because it embraces the full diversity of mitochondrial biology. It offers a comprehensive, top-to-bottom perspective on mitochondria, while bringing together a diverse group of scientists from across the field. This conference strikes a great balance of fresh perspectives and established expertise.
Jain: Because the symposium is intentionally small and highly interactive, you don’t just hear about exciting science; you immediately start brainstorming with the people behind it. That intimacy accelerates collaborations and often launches entirely new directions.
MitoWorld: Is there a risk of being too inclusive, with too many subjects? On the other hand, the field is still emerging. How do you strike a balance?
Fabbiano: The natural risk of such a broad field is thus the breaking down into silos and overspecialization, with each subfield narrowing down their perspective on the individual questions they are answering. Our vision and mission with this meeting are instead to go in the opposite direction, and we make it clear starting from the title: mitochondrial research is multifaceted, and should be appreciated as such to truly push the field forward. What makes us unique is our ongoing mission of strengthening the ties of a diverse community to create new channels of communication, new forms of collaboration, and develop ideas throughout a conference that welcomes both established leaders and emerging voices in the field.
Jain: Multifaceted Mitochondria is the rare meeting where every dimension of mitochondrial biology comes together—from metabolism and genetics to disease and therapy. It’s a unique opportunity to see the whole field at once and spark ideas that wouldn’t emerge in siloed settings.
MitoWorld: For the Glasgow symposium, what did you concentrate on. How did you determine the strands and the array of speakers? What do you hope people come away with?
Langer: It was of utmost importance to us to develop a program that only allows leading experts to discuss their most recent discoveries but also offers plenty of opportunities for young scientists to present their work and interact with other scientists in the field. We hope that the attendees will experience a vibrant and interactive scientific community and will leave with new tools, ideas and collaborators to further push forward the mitochondrial field.
Jain: Mitochondrial biology is advancing at an incredible pace, and this meeting is built to capture that momentum. We want participants to leave with new tools, new collaborators, and a clear sense of the frontier we’re all pushing toward.MitoWorld: What do you find exciting and challenging about organizing a Multifaceted Mitochondria Symposium, given the complexity of the fast-growing field and its many facets?
Langer: It is an exciting possibility and fun to bring together scientists working on different aspects of mitochondrial biology in a small and interactive setting to exchange their discoveries and ideas for new research directions. If I must mention something challenging, then that it is to select speakers among the many excellent scientists to build a program that covers the many aspects of mitochondrial biology and that allows us to identify synergies as a basis for future collaborations.
MitoWorld: It is refreshing to have a leading journal, in this case Cell Metabolism, take on a whole field-in-the making. It sounds like the journal has a hands-on approach with its communities.
Fabbiano: One point that makes us unique is the editorial involvement at these conferences, not only in the organization but in our very presence and engagement with the community. We appreciate that publishing can be a complex experience, and part of our mission with these conferences is also the direct contact with the community to address misconceptions and pain points around peer review and scientific publishing
MitoWorld: Given that approach, how do you interact with the research community in the journal and for a symposia, such as the Multifaceted Symposium?
Buttery: Our meetings are organized by and for the readers, authors, and reviewers that make our journals possible. They reflect the latest directions of the field, address controversies, and are curated in content and size to ensure that everyone from a young graduate student to a tenured professor learn something new and go back to their project with renewed enthusiasm and passion. That is definitely the case for us editors, too.
Important Deadlines:
Abstract submission deadline: February 13, 2026
Early registration deadline: April 10, 2026
Long associated only with energy and somewhat ignored, mitochondria are now recognized as key components in development and disease. On December 12, nearly 550 researchers met in person and virtually at Columbia University to assess the accomplishments and future directions of the Mitochondrial Stress, Brain Imaging, and Epigenetics—MiSBIE study. The study (Kelly et al. 2024) sought to understand the role of mitochondria and energy in mind-body processes and mitochondrial diseases. The “mother paper” (Kelly et al.), as they call it, also spawned other papers.
Symposium organizer Martin Picard (professor of behavioral medicine, Columbia) began by describing the holistic approach to the study. “We want to understand you as a person,” they emphasized to each study participant, as they welcomed them for the 2-day protocol in Manhattan.
Humans can be studied at various levels, including the molecular, cellular, tissue and organ, individual, and populations. The study sought to elucidate the interconnections of these levels through the lens of energy. More specifically, the MiSBIE team focused on the interactions of the immune system, mitochondria, the brain and nervous system, stress hormones, cognition, and behavior. Picard emphasized the importance of working as a team by noting the adage, “If you want to go quickly, go alone. If you want to go far, go together.” The discussions that followed featured several of his research group who contributed to the study.
Brain Mitochondria: The Energetic Landscape
In parallel with integrating mitochondrial energetics with psychobiology, the team developed the first mitochondrial map of the brain (Mosharov et al., 2025), a process led and described by Michel Thiebaut de Schotten (director of research, NeuroCampus of the University of Bordeaux). To link cognitive neuroscience and cell biology, they divided a frozen human coronal hemisphere section into 703 cubes or voxels (3 × 3 × 3 mm). Then, they defined the mitochondrial phenotypes (e.g., oxidative phosphorylation (OxPhos) enzyme activities, mitochondrial (mt)DNA and volume density, and mitochondria-specific respiratory capacity) in each voxel. The map revealed different characteristics for each region of the brain. If validated, the MitoBrainMap v1.0 of mitochondrial phenotypes might eventually allow exploration of the energetic landscape of normal brain function and correlations with standard neuroimaging methods—by magnetic resonance imaging (MRI).
“If this works, it would really be game changing,” said Picard. “You beam energy at the brain with a big magnet, then capture energy coming out of the brain, and somehow that tells you something about the biology of mitochondria. Amazing if this works.”
Building on the MiSBIE neuroimaging dataset, Tor Wager, PhD (professor of neuroscience, Dartmouth) and postdoctoral fellow Ke Bo examined behavioral and cognitive tasks through an energy-focused lens. One of their goals was to identify useful brain neurologic signatures associated with mitochondrial disorders. The molecules GDF15 and FGF21 show the strongest differences between individuals with mitochondrial disorders and controls. Wager used fMRI imaging to look for patterns in response to different tasks. These include cognitive (working memory, executive function tests), affective (cold pain), and sensory (multisensory with lights and stresses). Some of the correlations to mitochondrial disorders include sensitivity to negative emotions, but not to heat. In summary, the team finds that some brain functions and neural circuits are selectively vulnerable to energy deficits (Bo et al. Biorxiv 2025), consistent with an energy tradeoffs or “triage” model of psychopathology.
Immune Cell Bioenergetics
The group then wanted to examine the bioenergetics of immune cells. Jack Devine described how they stratified the phenotypes (or mitotypes) of immune cells. He used a new method developed by Anna Monzel, called mitotyping. Using principal component analysis, hierarchical clustering, and downstream analysis, they analyzed single immune cells from 164 people (ages 26–84). The MiSBIE team found that different types of immune cells have distinct patterns of activity (e.g., OxPhos, glycolysis) and aging.
To measure the bioenergetics of those cells from individuals with mitochondrial disorders, the group used extracellular flux analysis (Seahorse). Anna Monzel explained the process in beautiful details. The MiSBIE team isolated blood cells—monocytes, lymphocytes, neutrophils, platelets—from fasting individuals. For each cell type, they then measured their oxygen consumption and extracellular acidification rates to estimate OxPhos and glycolytic activities, using drugs that block specific enzymes in the mitochondria. OxPhos capacity was reduced in some cell types (not all) in people with mitochondrial disorders, but glycolysis was largely unchanged.
Using a biochemical approach called the mitochondrial respiratory capacity (MRC, formerly the Mitochondrial Health Index, MHI), Cynthis Liu examine mitochondrial biology in the same cells, of the same MiSBIE participants. She then used these data to explore the psychobiological relationships of immune cell mitochondria and mood symptoms, including anxiety and depressive symptoms. The work focused on mitochondrial respiratory chain at complexes I, II and IV, citrate synthase, and mtDNA content. The conclusion was that the maximal energetic capacity of immune cells is largely intact in mitochondrial diseases. Immune mitochondria are thus unlikely to reflect mitochondrial energetics in other tissues, such as the brain, muscles, and other organs.
Health Indicators: Time Perception
The MiSBIE study then focused on the indicators of health for those with mitochondrial disease. Two of these are the perception of time and allostatic load. Darshana Kapri examined the relationship of mitochondria to time perception. Individuals perceive time differently. Some people’s internal clocks run faster or slower than the actual time. Mitochondrial disorders didn’t directly affect time perception (faster or slower) but seemed to affect how potential drivers of time perception, including stress/metabolic hormones, such as norepinephrine, or metabolic rate. The team also discovered potentially meaningful associations between symptoms of burnout and fatigue and time perception, which demand validation in future studies.
Alex Junker then looked at allostatic load—a multi-system metric of physiological dysregulation known to predispose to disease. Allostatic load was higher in people with mitochondrial diseases and strongly correlated with lifetime stress and trauma. So genetics is important, but those with disease might be affected by their lived environment and the psychosocial factors that surround them. This new knowledge could motivate interventions or approaches that can provide additional support for those who have mitochondrial diseases.
Energetics of Stress: Cell-Free Mitochondria
The study also focused on the energetics of stress. Natalia Bobba-Alves described how the group developed a stress reactivity protocol and the effects of mitochondrial disorders. That protocol, which included eight concurrent blood and saliva collection timepoints over a 2-hour period, was used to study several stress mediators. The main stressor was a 5-minute speech task where participants had to give a speech in front of a white coat-wearing intimidating evaluators, while being (mock) videotaped.
David Shire explained their work on cell-free mtDNA in saliva and blood and stress. Levels of cell-free mtDNA are elevated in patients with cancer, heart disease, and inflammation. Higher levels of cf-mtDNA were detected in saliva than in serum or plasma from the same person. Stress caused a nearly 10-fold elevation in saliva cf-mtDNA within 10 minutes on average.
Mangesh Kurade presented results on FGF21 levels after the same stressor. The levels are significantly elevated in people with mitochondrial disorders. They decrease from morning to afternoon, and tend to be higher in people with higher body fat and in older people. Mental stress decreased plasma FGF21 in most control individuals, whereas it caused a robust increase in people with mitochondrial disorders—a remarkable divergence.
Caroline Trumpff looked at whether mental stress altered the mitochondrial disease biomarker GDF15. This molecule is the most robust available marker of mitochondrial disorders and energetic stress. The MiSBIE team found that psychological stress alone is sufficient to causes GDF15 levels to rise, both in blood and in saliva. This new discovery links mental and energetic stress, suggesting that both might converge on mitochondria and reductive stress, the key trigger for GDF15 release.
Future Directions: Hypermetabolism and mtDNA Instability
Evan Shaulson covered an ambitious follow up study: the Mitochondrial Daily Energy Expenditure (MDEE) study. Individuals with OxPhos defects often have fatigue and a short lifespan—on average reduced by 3-4 decades. Evan Shaulson described in vitro experiments from Gabriel Sturm on patient-derived fibroblasts, where subjecting cells to conditions that disrupted OxPhos doubled cellular energy expenditures. This state of hypermetabolism was associated with mtDNA instability, activation of the integrated stress response, and secretion of age-related cytokines and metabokines.
In the new MDEE study (manuscript in preparation), additional experiments were conducted with volunteers who spent a day in a small room while their metabolic rates, activity levels, and other psychobiological parameters were carefully and continuously measured. Half of the volunteers had a mitochondrial disease, and the other half were healthy controls—as in MiSBIE. For a further 8 days, MDEE participants lived their normal lives. The study found that like the fibroblast experiments, individuals living with OxPhos defects experience hypermetabolism. Thus, in both isolated cells and people, mitochondria with defects result in hypermetabolism and reduced lifespan, the connection between which remains to be better understood. This may relate, as the team proposes, to energy constraints that force deleterious tradeoffs where stress-related processes compete with health and healing-promoting processes.
Martin Picard summed up the symposium by focusing on a major gap in knowledge: “Healing is a set of dynamic, energetic processes by which an organism moves towards optimal function. Healing involves growth and development, recovery from injury, and adaptation that increase coherence and efficiency across the organism. Although healing is most likely the key driver of health, and the basis for not getting sick in the first place, we don’t have a science of this. We need a science of healing,” he said, pointing to their work around the science of health, and a new initiative to be unveiled in the coming year.
“Rational, scientific ways to harness the healing process would likely lead to new treatments and interventions that help optimize mitochondrial energy transformation. That would likely then contribute to more coherent and efficient psychobiological processes, freeing up energy to fuel the healing process and sustain health across the lifespan.”
The MiSBIE Symposium concluded with a reception that celebrated the scientific success of the NIH-funded study, supported by Baszucki Group. “MiSBIE sets the table for a new phase in the evolution of health sciences. Understanding psychobiological processes at an energetic level provides a foundation to develop a true science of healing: Healing Science,” said Picard. “There is a lot to be excited about. And we need everyone on board, not just scientists, to come along and join the movement.”
References
Kelly C, Trumpff C, Acosta C, Assuras S, Baker J, Basarrate S, Behnke A, Bo K, Bobba-Alves N, Champagne FA, Conklin Q, Cross M, De Jager P, Engelstad K, Epel E, Franklin SG, Hirano M, Huang Q, Junker A, Juster R-P, Kapri D, Kirschbaum C, Kurade M, Lauriola V, Li S, Liu CC, Liu G, McEwen B, McGill MA, McIntyre K, Monzel AS, Michelson J, Prather AA, Puterman E, Rosales XQ, Shapiro PA, Ghire D, Slavich GM, Sloan RP, Smith JLM, Spann M, Spicer J, Sturm G, Tepler S, Thiebaut de Schotten M, Wager TD, Picard M, The MiSBIE Study Group (2024) A platform to map the mind–mitochondria connection and the hallmarks of psychobiology: The MiSBIE study. Trends in Endocrinology & Metabolism (10): 884–901.
Mosharov EV, Rosenberg AM, Monzel AS, Osto CA, Stiles L, Rosoklija GB, Dwork AJ, Bindra S, Junker A, Zhang Y, Fujita M, Mariani MB, Bakalian M, Sulzer D, De Jager PL, Menon V, Shirihai OS, Mann JJ, Underwood M, Boldrini M, Thiebaut de Schotten M, Picard M (2025) A human brain map of mitochondrial respiratory capacity and diversity. Nature 641: 749–758.
Sturm G, Karan KR, Monzel AS, Santhanam B, Taivassalo T, Bris C, Ware SA, Cross M, Towheed A, Higgins-Chen A, McManus MJ, Cardenas A, Lin J, Epel ES, Rahman S, Vissing J, Grassi B, Levine M, Horvath S, Haller RG, Lenaers G, Wallace DC, St-Onge M-P, Tavazoie S, Procaccio V, Kaufman BA, Seifert EL, Hirano M, Picard M (2023) OxPhos defects cause hypermetabolism and reduce lifespan in cells and in patients with mitochondrial diseases. Communications Biology 6(1): 22.
https://www.nature.com/articles/s42003-022-04303-x.pdf
It’s time for a science of health, and a good look at the science behind the healing process. It looks likely that mitochondria play a central role in our ability to heal and be resilient. – Martin Picard, Columbia University
Martin Picard, PhD, runs the Mitochondrial Psychobiology Lab at the Columbia University Irving Medical Center. He and his students and colleagues, including Caroline Trumpff, a clinical psychologist and epidemiologist by training—now a mitochondrial psychobiologist—have deeply phenotyped healthy individuals and people with mitochondrial diseases. Picard, Trumpff, and the MiSBIE team devoted themselves to conducting psychological, stress and other biological investigations that are not strictly in the category of diseases, mutational consequences, or medical conditions. This has led to a rich body of investigations, studies and findings, including being part of a team that mapped mitochondrial distribution across all brain structures for the first time. Some of these investigations of energetics and stress do relate to underlying issues in medicine.
With NIH funding the Picard Lab assembled and led MiSBIE, a five year set of investigations and papers that will be reported out at the upcoming MiSBIE Symposium at Columbia University, and online, on December 12. The details are below, after MitoWorld’s interview with Dr. Picard.
MitoWorld: Martin, tell us about MiSBIE, how it came about, what it is.
Picard: MiSBIE is the Mitochondrial Stress, Brain Imaging, and Epigenetics Study. It was born in 2016, and it ran between 2018 to 2023. I put most of my startup funds into it—the most important study I thought my lab should focus on for the years to come. It was also the human translation of a 2015 preclinical study that showed that mitochondria regulate stress responses in mice. Now we’re 10 years later and we’ve learned a lot, which we’ll discuss at the Symposium on December 12th.
MitoWorld: Who should attend the 2025 MiSBIE Symposium?
Picard: Anyone interested in learning about mitochondria, stress, and health should find something of value at the symposium. Researchers in mitochondrial psychobiology and related fields may find details of the latest work in this area of interest. There will be relevant data and findings for clinicians who care for patients with primary mitochondrial diseases. And Mito patients may appreciate seeing the team unearthing new principles and findings that may eventually affect their care and empower them to achieve their full health potential. Entrepreneurs may also see opportunities in new mind-mitochondria connections discovered through MiSBIE. Finally, funders and philanthropists may find valuable lessons from the success of this deeply interdisciplinary study.
MitoWorld: Who is presenting and can you provide some URLs on what will be discussed, background papers?
Picard: Symposium presentations will be by scientists and students who have directly contributed parts of the MiSBIE study. You’ll hear directly from the team that conducted the study, and who are now performing analyses to understand the mind-mitochondria connection. The best background paper is the MiSBIE Mother Paper. Other MiSBIE data papers on the effects of mental stress on the metabokines FGF21 and GDF15, and on cell-free mtDNA, immune cell mitochondrial biology and symptoms, immune cell stimulation, and neuroimaging signatures have been published in final form or as preprints. All PDF are freely available on our website www.PicardLab.org/Publications
MitoWorld: What do you hope the outcome to be? What is the take away? And what do you hope to stimulate?
Picard: I hope people leave the MiSBIE Symposium inspired, with a new sense of the energetic processes underlying stress responses, brain processes, immune regulation, and the energetic cost of life. The key take away is that the energetic and molecular state of our mitochondria is linked to our experiences. More research is needed to bring energy into medicine, and to develop a more holistic model of what human health actually is. Most of biomedicine is about diseases—it’s time for a science of health, and a good look at the science behind the healing process. It looks likely that mitochondria play a central role in our ability to heal and to be resilient.
MitoWorld: Where can people register?
Picard: People can attend on Zoom or in person, and register at www.PicardLab.org/MiSBIE. We expect 400-500 people—there is room for everyone!
Details on the upcoming December 12 Symposium
The Mitochondrial Stress, Brain Imaging, and Epigenetics (MiSBIE) study was developed to understand the role of mitochondria and energy more generally in mind-body processes, as well as their potential relevance to people with mitochondrial diseases. At this Symposium, MiSBIE investigators and the international team of collaborators will share findings addressing some of the hypotheses we originally set out to test, plus some unexpected discoveries made along the way. The dataset and analyses conducted to date have linked mitochondria to immune, neuroimaging, endocrine, metabolic, psychosocial, and clinical outcomes relevant to the mind-mitochondria connection. We welcome you and your team to learn, discuss, question, and ideate to develop new collaborations.
The symposium will close with:
- Discussion around opportunities and future directions with the MiSBIE dataset.
- A poster sessionfor MiSBIE investigators and attendees wishing to present mitochondrial psychobiology-relevant research.
- A celebratory receptionwith mito-friendly food and drinks to commemorate MiSBIE’ success.
A Divided Community
In a September 2025 Viewpoint published in Nature Metabolism entitled “Mitochondria Transfer,” the editors noted, “. . . the topic continues to be met with skepticism.” As a result, the journal asked nine mitochondrial biologists to share their personal views on intercellular mitochondria transfer. There was little new here.
Their responses amounted to yes, no, and maybe. Many questions loom for otherwise promising results. What are the mechanisms and consequences of this process? If mitochondria do move between cells endogenously, when they arrive in another cell, do they resume their normal functions? Does the transfer of a relatively small number of mitochondria have the power to rescue a cell that is under bioenergetic stress?
At MitoWorld, we know most of the Viewpoint respondents, and we know the gulf between them. By kicking off debate, Nature Metabolism has started a process that we hope can mature from rhetoric to a more evidence-based picture of the efficacy of mitochondrial transfer and transplantation. Across the globe, investigations are underway in both categories. Given the limited mechanistic understanding of this process, it is surprising that mitochondrial transplantation is now a not uncommon medical intervention and remains a tantalizing subject of research and development in a variety of biotech companies.
First Step: Nomenclature
In all of this, there is a blurring of terminology. In January, Jon Brestoff and Keshav Singh, et al. published “Recommendations for mitochondria transfer and transplantation nomenclature and characterization,” also in Nature Metabolism. What is clear in their paper’s title is the notion of i) transfer being endogenous, part of an intrinsic biological mechanism and ii) transplantation, the act of deliberately introducing mitochondria into organs, tissues, and cells being exogenous. Over 30 researchers participated in what was a laudable effort to explore agreed-upon naming, processes, and explanatory conventions. While the consensus statement and an agreement for an International Committee on Mitochondria Transfer and Transplantation Nomenclature (ICMTTN) represents an important step forward, notable disagreements persist. Foremost among the complications related to mitochondrial transfer and transplantation relates to the unknown fate of any mtDNA harbored by incoming organelles.
Second Step: Conference
MitoWorld found itself in the middle of this controversy when it was asked to help with the first Mitochondrial Transplantation Conference. Held in April at Hofstra University, the event was organized by Northwell Health and led by Lance Becker. It featured a mix of compelling medical intervention talks and video for failing hearts (James McCully), treatment for stroke victims (Melanie Walker), and other resuscitation experiments with animals (Lance Becker). MitoWorld assisted in having endogenous transfer represented (Jonathan Brestoff). In all of this, there was excitement but also apprehension that parents of children and adults with mitochondrial genetic diseases will be given false hope for near-term treatments. Several drug developers were present, as were patient groups. It is likely some form of transplantation organization will emerge from that meeting.
Deeper Dive—Transfer and Transplantation
Given the lack of evidence-based dialogue, MitoWorld reached out to the Viewpoint respondents who are actively doing work in both categories. Yasemin Sancak, The Sancak Lab, University of Washington Pharmacology, and Rubén Quintana-Cabrera, Neurometabolism and Mitochondrial Dynamics Lab, Instituto Cajal, CSIC responded to MitoWorld.
MitoWorld: Why do you think there is such a controversy about mitochondria transfer and transplant?
Sancak: Transfer of mitochondria between cells is shown in different organisms and systems, and although this is relatively novel finding, it is widely accepted in the field. However, mitochondria transplantation attracts skepticism. In my opinion, the controversy stems from the expectation that, for mitochondrial transplantation to work as intended, the transplanted mitochondria should successfully incorporate into the host tissue in large numbers and maybe survive there for a long time, integrate into the donor tissue, and restore mitochondrial function and tissue health. Currently, the evidence of this happening is limited, and mechanisms of mitochondrial entry and survival are not well understood. But we also cannot ignore the exciting data that show the utility of mitochondrial transplantation in the clinic. Until we understand the molecular details and mechanisms of this process, the controversy is likely to continue. The field needs more preclinical and clinical research to understand mechanisms of therapeutic benefit and to establish clinical guidelines.
Quintana-Cabrera: These are quite novel concepts, now widely accepted by the scientific community after solid data in different cells and tissues. My perception is that both general and even specialized audiences are mostly focused on the incorporation of healthy mitochondria from neighboring cells or tissues to enhance mitochondrial activity in the compromised recipient cell. However, we should not overlook the transfer of damaged mitochondria, which may also benefit a cell by enabling their elimination through surrogate degradation in neighboring cells. Regarding transplants, the apparent controversy mainly concerns the injection of isolated mitochondria. Transplants using donor cells, such as mesenchymal stem cells or mitochondria encapsulated in vesicles or artificial membranes are viewed as able to better withstand the extracellular environment and the journey through the body to the target tissue. However, those advocating for transplants of isolated mitochondria need to standardize the approaches and to clarify how mitochondria survive outside the cell, influence inflammation, and integrate into recipient cells, or if they can take over native mitochondrial function in the long term.
MitoWorld: What may convince you that transfer happens naturally and/or that transplantation has effects?
Sancak: Many animal and cell culture studies show that mitochondrial transfer happens naturally, and this process is likely to serve different functions. Mitochondrial transplantation research in a pre-clinical setting mostly shows positive outcomes, but the long-term benefits of mitochondrial transplantation are not addressed. A small number of human studies show clinical benefit, but these are mostly feasibility and safety studies that were conducted with a small number of patients. One promising common finding from human studies so far is that mitochondrial transplantation does not seem to have any adverse effects and is generally considered to be safe. I think this is very promising and should open the door to bigger clinical trials. Ultimately, well-controlled clinical trials are needed to determine if mitochondrial transplantation will work for a disease of interest and what long term effects will be.
Quintana-Cabrera: A growing body of evidence demonstrates the natural occurrence of different types of transfer, mediated by tunneling nanotubes, microvesicles, or naked mitochondria, across various tissues and both in physiology and pathology. This is leading the scientific community to accept mitochondrial transfer as a naturally occurring event.
Of course, this is still a young field, and existing gaps need to be addressed by thoroughly evaluating the various dimensions of mitochondrial transfer. For example, further progress is needed in the assessment of intercellular communication mechanisms, such as tunneling nanotubes, which contribute to mitochondrial transfer but are technically challenging to study in vivo. Transplantation can produce meaningful effects, at least in the short term, depending on the delivery method, dosage, and source of mitochondria. Additional manipulations may enhance mitochondrial integration, modulate immune responses, or improve targeting to the appropriate tissue. However, it remains essential to understand how transplanted mitochondria interact with a much larger population of resident ones and to characterize both the short- and long-term effects of transplantation. This knowledge will help determine which strategies are truly beneficial. Such benefits may arise from whole mitochondria, their components, or even from transient cellular responses triggered by the presence of exogenous mitochondria.
MitoWorld: What do you say to those who contend that transplantation, at best, is a reaction to the presence of transplanted mitochondria, not that transplanted mitochondria are functionally integrated into recipient cells?
Sancak: This is an important question that highlights the significance of understanding what happens at the molecular level once the external mitochondria are delivered to the recipient cells. Most animal experiments show that the transplanted mitochondria must be functional to provide a positive outcome in the recipient cells. This suggests that the recipient cells’ reaction to presence of transplanted mitochondria is not the whole story, and transplanted mitochondria function is important. I think it is more likely that both mechanisms will play a role, and depending on the disease, transplantation method, and recipient cell, one mechanism may play a more prominent role than the other.
Quintana: This is a critical question that indeed needs clarification. Are transplanted mitochondria directly restoring function, or are they instead exerting indirect effects that still benefit the recipient cell or tissue? The latter could involve activation of stress-response pathways that partially restore homeostasis. Again, the source or method to deliver mitochondria may be key to what response is engaged, and the functional integration of mitochondria may not always be necessary to explain beneficial outcomes. Depending on the kind of transfer, whole mitochondria, or at least mitochondrial DNA, may escape degradation and integrate into the acceptor cell. Even in this scenario, we still need to assess whether and how their contribution reconfigures the native mitochondrial content, and what other events may occur in parallel.
MitoWorld: What does your research from actual cases tell you about what the transplanted mitochondria are actually doing?
Sancak: The transplantation studies I was involved in were focused on safety, and no clinical outcomes other than safety were monitored rigorously. What I can say is that mitochondrial transplantation appears safe in every system tested, which makes it more appealing to pursue as a potential therapeutic intervention. We still need to systematically investigate which mitochondrial functions are the most important.
Quintana: We observe spontaneous mitochondrial transfer in the nervous system, particularly at neuron-glia connections, in both healthy tissue and in pathological contexts, such as glioblastoma. The latter represents another dimension of transfer, where cancer-neural connectivity and mitochondrial exchange are emerging as key factors in cancer progression. We see that, in physiological contexts, transfer occurs spontaneously and is regulated by specific molecular players involved in intercellular communication and dynamics. Notably, we observe that different ways of transfer or mitochondrial acquisition serve to reconfigure the mitochondrial signature and metabolism in the nervous system and glioblastomas, with the potential to modulate their physiology and offer new venues for therapeutic interventions.
Recommendation
Having been involved in this topic for some time, MitoWorld has discussed a simple step toward moving from debate to a methodology to review what is being discovered in mitochondrial transfer (endogenous) and what is being performed in mitochondrial transplantation (exogenous). Here are the suggestions and more are welcome from the community.
- Establish a working group to track developments
As Brestoff, Keshav, et al. did with nomenclature, MitoWorld suggests the establishment of an agreed-upon tracking system for transfer and transplantation activity. This could be a formal registry, an inventory, or catalog. It will include common terminology and naming of activity, methods, collection, evidence, results, conclusions, and recommendations. We are asking a number of researchers to help in this process.
- AI review of literature and associated data
MitoWorld has a relationship with Heureka Labs, developed in part by mitochondrial and metabolic researcher and AI specialist Matthew Hirschey, PhD (Duke University School of Medicine). Heureka will develop an initial approach to use AI to index past research for categories of activity and to develop data standards for analyzing and synthesizing data and processes.
- Basic science and the phenomenology of mitochondria
There is still much to learn about our endosymbionts, the mitochondria, along with their DNA, and the complex mitonuclear system. Mitochondria have suffered years of obscurity in many forms of research and medicine. They have been typecast as the powerhouse of the cell. mtDNA is just beginning to be a larger topic, with the first conference on the subject having been held this summer in Nashville, Mechanisms of Mitochondrial DNA Mutation and Repair. We would like to see the still poorly understood mechanisms of mitochondrial biology become more central to funding agencies around the world, as it is increasingly apparent that mitochondria, as the hubs of metabolism, are central to the health of our cells.
A collective effort across the mitochondrial research and clinical communities has sought to play down the “powerhouse of the cell” phrase as the sole description of mitochondria and, instead, to elevate the amazing multiplicity of mitochondrial functions. Top among those functions is mitochondrial signaling. The leaders in the signaling field will be gathering at the Keystone “Mitochondria Signaling in Physiology and Disease Symposium,” Feb 09–12, 2026, at the Keystone Resort, Keystone, Colorado in the U.S, whose keynote speaker is Anu Suomalainen Wartiovaara, University of Helsinki, presenting “Lessons Learned from Patients with Mitochondria Mutations for Physiology and Diseases.” [Conference Flyer]
Scientific organizers, Navdeep Chandel, Northwestern University Feinberg School of Medicine, and Aleksandra Trifunovic (video), Institute for Mitochondrial Diseases and Aging, University of Cologne, among the most published on the topic, have brought together a very strong group of international speakers to present findings and stimulate dialog. Among them is José Antonio (Tonio) Enríquez, Professor and Group Leader of the “Functional Genetics of the Oxidative Phosphorylation System (GENOXPHOS)” Laboratory at the Spanish National Center for Cardiovascular Research (CNIC) in Madrid, Spain.
Because of Tonio’s expertise in mitochondrial bioenergetics, oxidative phosphorylation (OXPHOS) and mitochondrial signaling and communication, MitoWorld asked him to answer a few questions about mitochondrial signaling and its significance to build the platform for understanding mitochondria more completely.
MitoWorld: What is the significance of this conference in terms of content, collaborations and the field of mitochondrial signaling?
Enríquez: This Keystone conference represents a pivotal moment in mitochondrial research, marking the formal recognition of mitochondria as central signaling hubs rather than mere energy factories. The conference, organized by Navdeep Chandel and Aleksandra Trifunovic, brings together field leaders who have fundamentally reshaped our understanding of mitochondrial biology over the past 25 years.
MitoWorld: Why is the conference important to do you individually? Can you introduce your area that relates to signaling?
Enríquez: My research area directly relates to signaling through the study of metabolic channeling and respiratory supercomplex assembly. These structures are not merely efficient ATP production units. They represent sophisticated signaling platforms that regulate ROS production, metabolite flux, and cellular stress responses. The spatial organization of respiratory complexes influences how electrons flow through the chain, affecting both energy production and generation of signaling molecules, such as superoxide and hydrogen peroxide. Furthermore, my work on aging mechanisms connects directly to mitochondrial retrograde signaling pathways that communicate cellular stress to the nucleus, triggering adaptive responses or, when dysregulated, contributing to age-related pathologies.
MitoWorld: It seems that “signaling” always must be added to any mitochondrial discussion to get beyond the APT/powerhouse conversations. Talk about how we should see mitochondria and mtDNA as part of the signaling functions in cells with the nucleus and beyond.
Enríquez: The persistent need to add “signaling” to mitochondrial discussions reflects decades of reductionist thinking that portrayed mitochondria solely as cellular powerhouses. This ATP-centric view, while historically important, has become a conceptual limitation that obscures the true complexity of mitochondrial function. Mitochondria and mtDNA function as integrated signaling networks with multiple mechanisms.
- Metabolite signaling: Mitochondria produce signaling metabolites (e.g., α-ketoglutarate, succinate, acetyl-CoA, and citrate) that directly regulate nuclear gene expression through epigenetic modifications. These metabolites serve as cofactors for chromatin-modifying enzymes, linking mitochondrial metabolism to nuclear transcriptional programs.
- ROS as signal transducers: Rather than just being toxic byproducts, mitochondrial ROS function as essential signaling molecules that activate stress-responsive pathways, regulate hypoxia responses, and control cellular fate decisions. The spatial and temporal regulation of ROS production allows mitochondria to communicate specific information about cellular energetic and redox status.
- Retrograde signaling pathways: Mitochondria communicate their functional status to the nucleus through calcium-calcineurin signaling, AMPK activation, and transcription factor regulation. These pathways allow cellular adaptation to mitochondrial dysfunction and coordinate nuclear gene expression with mitochondrial needs.
- mtDNA as an inflammatory signal: Cytoplasmic release of mitochondrial DNA activates innate immune pathways through cGAS-STING signaling, linking mitochondrial damage to inflammatory responses. This represents a fundamental immune surveillance mechanism that monitors mitochondrial integrity.
MitoWorld: List and discuss the various types of signaling and the ones you personally are interested in.
Enríquez: The diversity of mitochondrial signaling mechanisms reflects the evolutionary origin and cellular integration of these organelles.
- Metabolite-mediated signaling: This includes one-carbon metabolism products (SAM, formate), TCA cycle intermediates (α-KG, succinate, fumarate), and lipid signaling molecules (cardiolipin, ceramide). These metabolites regulate epigenetic modifications, transcriptional programs, and enzymatic activities throughout the cell.
- ROS Signaling: Different mitochondrial sites produce distinct ROS species with specific signaling functions. Complexes I and III generate superoxide with different submitochondrial localizations, affecting cytoplasmic versus matrix signaling pathways. H₂O₂ serves as a diffusible signaling molecule that modifies cysteine residues on target proteins.
- Calcium signaling: Mitochondria function as calcium buffers and signal processors, with calcium uptake and release coordinating with cellular calcium oscillations to regulate gene expression, enzyme activities, and cellular excitability.
- Mitokine secretion: Mitochondrial stress triggers the release of signaling proteins, such as FGF21, GDF15, MOTS-c, and Humanin, that act in autocrine, paracrine, and endocrine manners to coordinate tissue responses. These represent a new class of stress-responsive hormones.
- Intercellular mitochondria or mitochondrial components transfer: Direct transfer of mitochondria or mitochondrial components between cells represents a mechanism for intercellular signaling that can modify recipient cell function.
- Epigenetic regulation: Mitochondrial function directly influences nuclear chromatin structure through metabolite availability, NAD+/NADH ratios, and histone modification enzyme activities. This creates a direct link between mitochondrial metabolism and gene expression programs.
Personally, I am most interested in ROS signaling mechanisms and metabolite-mediated epigenetic regulation, as these directly relate to my research on respiratory complex assembly and aging mechanisms.
MitoWorld: If we are to re-define mitochondria how important is signaling and what might the inclusive definition include?
Enríquez: Signaling is critically important because it represents the mechanism by which mitochondria integrate their traditional functions with cellular and organismal physiology. Without signaling, mitochondria would be isolated organelles incapable of coordinating their activities with cellular needs or communicating their status to other cellular compartments. The new paradigm recognizes mitochondria as “cellular command centers” that process information, make decisions, and coordinate responses rather than simply executing metabolic programs
MitoWorld: For newcomers to the field, what would you tell them in terms of the importance of signaling in general and mitochondrial signaling in particular?
Enríquez: For students and PhD candidates entering the field, I would emphasize several key points.
- Understanding signaling as fundamental biology: Every cellular process, from development to disease, involves signaling networks. Students should approach mitochondria as integrated systems rather than isolated organelles.
- Interdisciplinary perspective is essential: Modern mitochondrial research requires integration of biochemistry, cell biology, physiology, bioinformatics, and clinical medicine. Students should develop broad competencies and collaborative skills to address complex mitochondrial questions.
- Technical diversity: The field requires expertise in diverse methodologies—from single-cell analyses and live imaging to omics approaches and animal models. Students should gain experience with multiple technical approaches to study mitochondrial function.
- Clinical relevance: Mitochondrial signaling dysfunction underlies numerous diseases, including cancer, neurodegeneration, metabolic disorders, and aging. Understanding the translational potential of basic research enhances both scientific impact and career opportunities.
Students must understand that signaling represents the mechanism by which mitochondria exert their biological effects beyond energy production. Dysregulated signaling, not simply energy deficiency, underlies most mitochondrial contributions to disease pathology.
www.MitoWorld.org is committed to raising public, professional and patient community awareness globally about mitochondria science, diseases, dysfunction and health. As a central resource, MitoWorld strives to share advances in mitochondrial research and clinical practice.
Guided by a senior scientific advisory board (SAB) comprising leading mitochondrial researcher and clinician-researchers and several mitochondrial medicine clinicians (Medical Advisors).
MitoWorld’s mostly volunteer Team includes three postdoc level gifted young investigators, a senior editor and writer, talented web developer and long-time patient and industry relations expert.
Together, this team with the advisory boards’ guidance produces, collects, and publishers external resources on the site and then internally produces a constant stream of high-quality original media.
- MitoBlog. We post on the latest research papers, profile mitochondrial researchers and clinicians, portray mitochondria labs globally, and report on major conferences.
- MitoCast. We conduct video interviews and accumulate information from leading researchers and clinicians.
- MitoNews. We post articles from outside sources and feature mitochondria newsfeeds from PubMed, Nature Portfolio, PRNewswire and Google on our homepage.
- Mito Events. Posting upcoming conferences and symposia and, in many cases, providing special coverage of the upcoming events through media partnerships with the conference companies and academic organizers.
- “Beyond the Disease”. In partnership with the United Mitochondrial Disease Foundation (UMDF.org), we compile a monthly set of papers to be published in their newsletter.
The core information resources on the site include a directory of leading mitochondrial researchers, academic institutions, patient organizations and clinical centers (LINK).
We are a participatory, community building nonprofit organizations. We invite inquiries, participants, and we are always looking for collaborators, supporters and funders. Feel free to reach out and help us build the “Mitochondrial Revolution” (Contact)
MitoWorld™ is a project of the California-based national R & D human capital and STEM nonprofit, National Laboratory for Education Transformation, NLET.
When Gordon Freedman, NLET’s founder and former journalist, discovered he had several mitochondrial disorders, NLET launched MitoWorld to help get the word out about the emerging potential of mitochondrial research to help across the health and disease spectrums.
If our website is MitoWorld, the Mechanisms of Mitochondrial DNA Mutation and Repair conference was the introductory gathering of what could be called “mtDNA World.”
The organizers, Patrick Chinnery (Cambridge), Agnel Sfeir (Sloan Kettering) and Michal Minczuk (Cambridge), emphasized that this conference focused solely on mtDNA is a first of its kind.
“This brand-new conference will focus on understanding how mitochondrial DNA mutations occur in the germ line and somatic tissues with age and how they contribute to common diseases, including neurodegeneration and cancer. The conference will also cover mitochondrial DNA’s molecular and cellular consequences and new approaches to repair and remove mutations.” [conference website]
The global mitochondria conference circuit generally is focused on mitochondria themselves (often in primary mitochondrial disease) in all their complexity with a smaller percentage of presentations on mtDNA itself. In Nashville, June 1–5, about 75 individuals representing labs globally, went deep into a range of heteroplasmy dynamics over lifetimes and in various disease and dysfunction cases. There was a sense of the importance of mtDNA and its relationship with the nuclear DNA as a primary and secondary driver of disease and dysfunction and also as part of the fundamental aging process.
“The result was an interactive meeting that highlighted the current multi-functional nature of mtDNA (beyond its known role in ATP production) and the cutting-edge new techniques and approaches now available to understand how mtDNA genes are expressed, how mtDNA mutations contribute to human physiology and pathology, and how we can now edit mtDNA or otherwise modulate this maternally inherited genome to improve human health,” said Gerry Shadel (Salk Institute).
The conference was very participatory and, since it was held in Nashville, ended with an evening of line dancing.
In the words of some of the organizers and attendees:
Agnel Sfeir, Organizer, Sloan Kettering
The meeting exceeded our expectations in every way. The quality of the science, the level of engagement, and the sense of community were truly exceptional. One of our goals was to create a space that fostered open discussion across disciplines and career stages, and I think we succeeded, which was evident by the engagement of trainees, the quality of their presentations, and the insightful questions they asked.
Dmitry Temiakov, Thomas Jefferson University
The conference’s exclusive focus on mitochondrial DNA was both timely and highly valuable for the scientific community. By concentrating on mtDNA, the meeting brought together researchers across diverse disciplines—from genetics and structural biology to clinical medicine—who might otherwise not engage in direct dialogue. This focused format fostered in-depth discussions on unresolved questions, including the mechanisms underlying mitochondrial diseases, maternal inheritance, and the role of mtDNA in inflammation and aging.
Maria Falkenberg, The Falkenberg Lab, University of Gothenburg
The meeting was a unique and refreshing experience, being the first to focus only on mtDNA. It gave space for interesting discussions that went all the way from basic science to possible new treatments. The talks covered many parts of mtDNA biology, from how it is maintained to how it can be targeted in disease. It was great to see the community come together around a topic that is often included in bigger meetings, but not usually the main focus.
Gerald Shadel, Salk Institute
Our genome comprises nuclear and mitochondrial DNA, both of which are essential for life and contribute to human diseases and aging. The biology and genetics of mtDNA is complex due to it being present in multiple (often thousands) copies/cell and its sequence dynamically changing in our bodies as we age. While there are many meetings on nucleic acids (DNA and RNA), genetics and even mitochondria, rarely is mtDNA a central theme. This FASEB meeting was therefore unique by focusing a lens on mtDNA and effectively bringing together many of the senior researchers who have long influenced our understanding of mtDNA with exciting new investigators in the field.
Carlos T. Moraes, University of Miami
It was right time for a meeting focused on my favorite genome (mtDNA). There have been so many advances in our understanding and manipulation of mtDNA in the last few years, and it was exhilarating to hear and discuss them with experts and colleagues. My recent area of work is mtDNA editing, and new techniques have opened a whole area of investigations and therapeutic development. As always, new knowledge raises many questions, so this meeting was a great forum to generate new ideas and how to overcome barriers, such as the off-target edits of mtDNA base editing.
Amutha Boominathan, MitoSENS
The conference provided a comprehensive overview of recent advances in mitochondrial DNA research, with a strong focus on its role in cellular function and pathology. A key highlight was the application of advanced sequencing technologies to resolve mitochondrial heteroplasmy at the single-cell level and to establish genotype-phenotype correlations. It brought together students and junior and established researchers, with particular emphasis on emerging topics, such as mitochondrial regulation of immune responses, novel metabolic functions, and targeted approaches to silence/modulate the mitochondrial genome. The meeting was highly interactive and engaging. Looking forward to the follow-up!
Olvia Conway, Duke University
This meeting was extremely valuable to me as a trainee because of the networking and learning opportunities available. My mtDNA project is a new area for the lab, so this meeting was a way to meet others focused on this topic, receive feedback on some of my early work, and determine in which direction the field is heading. I am grateful for the opportunity to talk to other scientists during the conference sessions, and I am planning on implementing many of the suggestions I received. This was my first meeting as a graduate student, and I had a great experience.
The UMDF Mitochondrial Medicine for Scientists and Clinicians Mitochondrial Medicine 2025 conference provides an international stage for leaders in mitochondrial medicine and offers programs to inspire the next generation of researchers. Attendees will learn about the latest developments in the field of mitochondrial medicine, including industry advancements, potential treatments, therapies and cutting-edge research. The event also gives the scientific communities the unique experience of engaging with affected patients to better understand symptoms and work faster towards a cure. This year’s conference is being held in St. Louis, Missouri on June 18-21, 2025. https://www.umdfconference.org/
Jonathan Brestoff, MD, PhD, MPH, leads the Brestoff Lab and is Associate Professor of Pathology & Immunology, Director of the Initiative for Immunometabolism, and Medical Director in the BJH Clinical Flow Cytometry Lab at WashU Medicine in St. Louis.
We asked Jon to explain a bit about this his work and what is being organized from the scientific and medical community at UMDF 2025.
MitoWorld: Jon, how did you become involved with the UMDF Clinical & Scientific Program?
Brestoff: My lab has been working on trying to develop mitochondria transplantation as a new therapy for primary mitochondrial diseases, and this work has gotten me engaged with the UMDF. With the meeting being in St. Louis, they sought a local presence on the organizing committee. I’m very honored to help with this meeting and think it will be very exciting!
MitoWorld: What can researchers and clinicians expect from this year’s program?
Brestoff: This conference includes an amazing lineup of speakers on diverse scientific topics on mitochondrial biology and clinical issues in mitochondrial medicine. Main scientific sessions include Inflammation and Metabolic Diseases, Mitochondria on the Move, Mechanisms of Clearing Damaged Mitochondria, and Multi-omics. Clinical sessions include the NAMDAC Registry Session, Mitochondrial Medicine Society Platform, and Clinical Trial Updates. On Saturday, there are 2 parallel Master Classes, one on emerging clinical topics chaired by Dr. Michio Hirano and one on scientific career development chaired by me.
MitoWorld: Is there any particular theme or emphasis this year?
Brestoff: The main themes are around emerging scientific discoveries about mitochondria and clinical updates. One of the most exciting aspects of this meeting is that patients, families, clinicians, and scientists all come together for one conference. This creates a unique experience that, in my experience, has been incredibly motivating and inspiring.
MitoWorld: With your lab at Washington University in St. Louis, will you be discussing or your lab members presenting on your lab’s work?
Brestoff: Yes! While I am not speaking to yield time to other investigators, a couple exceptionally talented scientists from my group are presenting their work on mitochondria transfer and transplantation.
MitoWorld: What are your hopes in your work for the next year and what issues are on the forefront that may materialize over the next year?
Brestoff: There are so many new and exciting discoveries about mitochondria — how they work, what they do, and how we can leverage their biology to develop new therapeutics. There is tremendous untapped potential in this field for many diseases, not just primary mitochondrial diseases but also others like obesity, heart disease, and even aging. I hope we can find ways to team up with each other, industry partners, and investors to make some of these new therapeutics a reality for patients who need them. For my own lab, we’re currently working to make mitochondria transplantation a future possibility for patients with primary mitochondrial diseases. I hope we can get there.